Department of Gynecology, Yuncheng Central Hospital of Shanxi Province, Yuncheng, 044000, China.
Department of Pharmacy, Yuncheng Central Hospital of Shanxi Province, Yuncheng, 044000, China.
BMC Womens Health. 2021 Mar 31;21(1):134. doi: 10.1186/s12905-021-01263-y.
This study aimed to investigate the clinical and pathological characteristics, and the recurrence and prognostic factors of borderline ovarian tumors (BOTs).
The data of 286 patients admitted to hospital and followed up for more than ten months were analyzed retrospectively to study the clinicopathological characteristics and related factors of recurrence.
The median age of the patients was 42.06 ± 14.97 years, and the duration of the follow-up ranged from 10-109 months. During the follow-up period, 40 patients had a recurrence. Of these patients, 36 were ≤ 40 years, and patients with premenopausal recurrence accounted for 20.5% (36/176). In patients undergoing conservative treatment or radical operations, the recurrence rates were 21.3% and 1.8%, respectively, and they were 13.4% (36/268) in patients at Federation International of Gynecology and Obstetrics (FIGO) stage I, and 22.2% (4/18) in patients at an advanced stage. Postoperative pathology revealed that 40 patients had micropapillary tumors, among whom ten patients (25%) had a recurrence, and 19 patients had complications with interstitial infiltration. Of these 19 patients, six had a recurrence (31.5%). Another 22 patients had complications with calcified sand bodies; among these, eight patients (36.4%) had a recurrence. All the differences were statistically significant (P < 0.05). There were four cancer-related deaths during the follow-up period. Late FIGO stage, conservative operation, and a high level of carbohydrate antigen 125 (CA125) were independent risk factors for the recurrence of BOTs.
BOTs usually occur in women under 40 years, have an occult onset, and half of the patients have no obvious clinical manifestations. Serum CA125 level can be used as a tumor marker to detect BOTs and the risk of its recurrence. Operation mode and FIGO stage are important independent factors for the recurrence of BOTs.
本研究旨在探讨交界性卵巢肿瘤（BOT）的临床病理特征、复发及预后因素。
回顾性分析 286 例住院并随访 10 个月以上患者的临床病理资料，研究复发的临床病理特征及相关因素。
患者中位年龄为 42.06±14.97 岁，随访时间 10~109 个月。随访期间复发 40 例，其中≤40 岁者 36 例，绝经前复发占 20.5%（36/176）。行保守手术或根治性手术者复发率分别为 21.3%、1.8%，国际妇产科联盟（FIGO）分期Ⅰ期者复发率为 13.4%（36/268），晚期者复发率为 22.2%（4/18）。术后病理见微乳头型肿瘤者 40 例，其中 10 例（25%）复发，间质浸润并发症 19 例，其中 6 例（31.5%）复发。钙化砂粒体并发症 22 例，其中 8 例（36.4%）复发。差异均有统计学意义（P<0.05）。随访期间死亡 4 例，均为肿瘤相关死亡。晚期 FIGO 分期、保守性手术、CA125 水平升高是 BOT 复发的独立危险因素。
BOT 好发于 40 岁以下女性，起病隐匿，半数患者无明显临床表现。血清 CA125 水平可作为肿瘤标志物用于检测 BOT 及其复发风险。手术方式及 FIGO 分期是影响 BOT 复发的重要独立因素。
